Rheumatoid Arthritis - Cimzia(R) Studies Show Significant Clinical Benefits For Mono- And Combination Therapy
Nov 21st 2008Drug InformationArthritis
UCB today announced the results of two phase III studies, published in the Annals of the Rheumatic Diseases Online, showing Cimzia® (certolizumab pegol), the only PEGylated anti-TNFalpha (Tumour Necrosis Factor alpha), provided significant clinical benefits as monotherapy, and in combination with methotrexate, in adults with active rheumatoid arthritis (RA).
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
